Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib and Tislelizumab in R/R PMBCL and EBV+ DLBCL
NCT04705129Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, tislelizumab in primary mediastinal large B-cell lymphoma (PMBCL), diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
zanubrutinibtislelizumab
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04705129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705129.